On 4/7/2017, Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed at $28.73 in last trading day. After noting the initial trading entry at $29.31, it reached to a day’s high of $29.37 and moved to a day’s low of $28.15. The recent daily volume was 1.83 million as contrast to it’s an average volume of 2.56 million.
The last close of the Sarepta Therapeutics, Inc. stock reflects that it traded -5.49% from its 50-day moving average of $30.40. The stock traded below -22.30% to its 200-day MA of $36.98. Furthermore, it moved lower -54.92% from its 52-week high of $63.73 and +259.12% up from $8.00, which is 52-week low of the stock.
Sarepta Therapeutics, Inc.’s (SRPT) moved with shift of -2.94% in the past week. Over the last three months, the shares of the company have changed -4.49% and performed -53.47% over the last six months. The stock currently has Monthly Volatility of 4.68% and Weekly Volatility of 4.61%.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children’s Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; and collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
General Communication, Inc. (NASDAQ:GNCMA) finalized the last transaction at value of $35.51, with a daily change of -0.28% or -0.10 points. The company maintained volume of 523.05 thousand shares. In past trading day, the stock hit the maximum price of $35.97 and touched to minimum value of $35.24. It has a market cap of $ 1.27B.
As of last trade close, the stock is trading downside -1.28% from its one year high of $35.97 and moved +189.64% upward from $12.26, which is one year low of the stock.
The stock traded above +78.07% from its 50-day moving average of $19.94. Furthermore, the stock moved up +102.50% to its 200-day MA of $ 17.54.
During the last month, General Communication, Inc.’s (GNCMA) has changed 91.02% and performed 144.90% over the last 6 months. The mean rating score for this stock is at 3.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 3.99% in recent month and observed Weekly Volatility of 5.29%.
General Communication, Inc. provides a range of wireless, data, video, voice, and managed services to residential customers, businesses, governmental entities, and educational and medical institutions under the GCI brand primarily in Alaska. It operates through two segments, Wireless and Wireline. The Wireless segment offers wholesale wireless services and products that provide network transport and access to company’s wireless network for wireless carriers. This segment sells its products through direct contact marketing. The Wireline segment offers a range of retail wireless, data, video, and voice services to residential customers; wireless, data, video, voice, and managed services to businesses, governmental entities, and educational institutions; wholesale data and voice services to common carrier customers; and regulated voice services to residential and commercial customers in rural communities primarily in Southwest Alaska. It sells its services through call center, direct mail and television advertising, Internet and local media advertising, and retail stores. The company also sells wireless handsets to retail customers. As of December 31, 2016, it had 222,500 wireless subscribers, 140,800 cable modem subscribers, and 125,800 basic video subscribers. General Communication, Inc. was founded in 1979 and is based in Anchorage, Alaska.